Last Updated: August 2, 2026

Details for New Drug Application (NDA): 022239

✉ Email this page to a colleague

« Back to Dashboard

NDA 022239 describes SUMAVEL DOSEPRO, which is a drug marketed by Endo Operations and is included in one NDA. There are two patents protecting this drug. Additional details are available on the SUMAVEL DOSEPRO profile page.

The generic ingredient in SUMAVEL DOSEPRO is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

Summary for 022239

Tradename:	SUMAVEL DOSEPRO
Applicant:	Endo Operations
Ingredient:	sumatriptan succinate
Patents:	2

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;SUBCUTANEOUS			Strength	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)
Approval Date:	Jul 15, 2009	TE:		RLD:	Yes
Patent:	7,776,007	Patent Expiration:	Nov 22, 2026	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	7,901,385	Patent Expiration:	Jul 31, 2026	Product Flag?	Y	Substance Flag?		Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:	DISCN	Dosage:	INJECTABLE;SUBCUTANEOUS			Strength	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)
Approval Date:	Nov 26, 2013	TE:		RLD:	Yes

Expired US Patents for NDA 022239

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Operations	SUMAVEL DOSEPRO	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	022239-001	Jul 15, 2009	6,280,410	⤷ Start Trial
Endo Operations	SUMAVEL DOSEPRO	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	022239-001	Jul 15, 2009	8,118,771	⤷ Start Trial
Endo Operations	SUMAVEL DOSEPRO	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	022239-001	Jul 15, 2009	7,901,385	⤷ Start Trial
Endo Operations	SUMAVEL DOSEPRO	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	022239-001	Jul 15, 2009	5,891,086	⤷ Start Trial
Endo Operations	SUMAVEL DOSEPRO	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	022239-001	Jul 15, 2009	8,241,243	⤷ Start Trial
Endo Operations	SUMAVEL DOSEPRO	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	022239-001	Jul 15, 2009	6,681,810	⤷ Start Trial
Endo Operations	SUMAVEL DOSEPRO	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	022239-001	Jul 15, 2009	8,287,489	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.